Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Share News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.60
Bid: 27.60
Ask: 28.60
Change: -1.05 (-3.66%)
Spread: 1.00 (3.623%)
Open: 27.60
High: 27.60
Low: 27.60
Prev. Close: 28.65
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EKF Diagnostics says prospects "promising" but pauses dividends

Wed, 20th Mar 2024 11:16

(Alliance News) - EKF Diagnostics Holdings PLC on Wednesday said it swung to profit in its latest year despite revenue falling.

Shares in EKF were down 1.7% at 26.20 pence late on Wednesday morning in London.

The Cardiff-headquartered medical diagnostics company reported a GBP2.1 million pretax profit for 2023, compared with the previous year's GBP8.9 million loss.

Losses from exceptional items totalled GBP2.8 million, compared with a GBP17.5 million loss in 2022.

Revenue decreased 21% to GBP52.6 million from GBP66.6 million, "in-line with market expectations". Excluding Covid-related and clinical chemistry sales, however, revenue increased slightly to GBP48.7 million from GBP48.6 million.

EKF said the reduced revenue reflects "significantly lower" Covid-related revenue; its disposal of the ADL laboratory testing business; and a GBP3.5 million one-off inventory recovery item in 2022.

For the Point-of-Care division, revenue rose 1.9% to GBP34.1 million. For the Life Sciences division, it fell 2.4% to GBP14.8 million.

"Despite the challenges during 2023, the senior management team has successfully refocused the business back to pre-pandemic levels," said Executive Chair Julian Baines.

EKF declared a final dividend of 1.2p per share for 2023, unchanged from the year before.

However, the company said it has decided to pause dividend payments, citing "the potential need for continued modest investment in the growth of our core areas". It will focus on "[enhancing] shareholder value mainly through growth" instead.

"The board will continue to review the option of recommencing dividend payments, but only if appropriate, and subject to the availability of surplus cash generation above the needs of the business," EKF added.

This year, EKF said it plans to focus on its higher-margin products and services.

"With a structured management team in place, a newly streamlined business, and the opening of our state-of-the-art fermentation facility in South Bend, we have a company that is well placed to deliver growth and improved returns from many of the investments made over the last two years," commented Baines.

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
28 Jan 2015 12:05

UK WINNERS & LOSERS: Gowin Rockets On Funding Agreement

Read more
28 Jan 2015 08:27

EKF Diagnostics Expects Full Year Results At Higher End Of Guidance

Read more
23 Jan 2015 08:23

UK MORNING BRIEFING: Shares Up, Pound Below USD1.50 After ECB Move

Read more
23 Jan 2015 07:52

EKF Diagnostic And ANGLE Combine Technologies For Cancer Study

Read more
17 Dec 2014 09:12

EKF Diagnostics warns on profit on currency hit and lower revenue from buys

Medical group EKF Diagnostics warned on annual profits after taking a currency hit and saying revenue from newly acquired companies was likely to be lower than expected. EKF said acquisitions during the year of Diaspect, Selah Genomics and STI were set to contribute at least £6.1m to overall revenue

Read more
1 Oct 2014 10:46

DIRECTOR DEALINGS: EKF Diagnostics Chairman Buys 100,000 Shares

Read more
30 Sep 2014 09:50

Tuesday broker round-up UPDATE

Aberdeen: Goldman Sachs ups target price from 540p to 560pp retaining a buy recommendation. African Barrick Gold: Deutsche Bank moves target price from 270p to 280p and reiterates a hold recommendation. Investec lowers target price from 260p to 258p, while upgrading to buy. African Minerals: Invest

Read more
23 Sep 2014 07:18

EKF Diagnostics Signs Research Deal With Massachusetts General Hospital

Read more
15 Sep 2014 11:10

UK WINNERS & LOSERS: Micro Focus Jumps 14% On Reverse Takeover Deal

Read more
15 Sep 2014 08:55

EKF On Track To Meet Full-Year Expectations Despite Swing To Loss

Read more
23 Jul 2014 09:04

EKF Confident In Meeting Market Expectations On First-Half Progress

Read more
23 Jul 2014 07:34

UK MORNING BRIEFING: Renishaw And Capita Lead London Shares Higher

Read more
8 Jul 2014 09:12

EKF Signs Distribution Contract; Partner Wins Regulatory Approval

Read more
2 Jun 2014 09:41

EKF Takes "Major Step" Towards Detecting Cancer In Blood; Appoints CTO

LONDON (Alliance News) - EKF Diagnostics Holdings PLC Monday said it has taken a major step towards detecting cancer cells in blood samples, and has appointed a new technology boss. Separately, EKF said it has appointed Tito Bacarese-Hamilton as its new Chief Technology Officer. Bacarese-Ha

Read more
2 Jun 2014 08:38

EKF Diagnostics takes big step in cancer detection

Medical group EKF Diagnostics says a partnership in which it is involved has made a major step towards detecting cancer in blood. EKF said first results from its collaboration with German group Gilupi had successfully shown detection of gene mutations from as few as three or less isolated cells and

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.